InKaryo has developed the most advanced bioinformatics analytical processing of NGS data for the detection and quantification of chromosomal numerical and structural abnormalities, improving and expanding the performance and resolution of GENOMA’s genetic tests portfolio.
InKaryo, the US-based company from Silicon Valley specialized in cytogenetic analysis through next generation sequencing (NGS) is a fully owned company of ESPERITE’s group. InKaryo, , was founded in California by a group of scientists with expertise in all major next generation sequencing platforms (454, SOLiD, GAII, HiSeq, MiSeq, Ion PGM, Ion Proton, and Complete Genomics), sequencing reagents, sequencing applications, genomic diagnostics, and bioinformatics with previous experience at Genomic Health, Life Technologies, Ion Torrent, Illumina, and Complete Genomics.
InKaryo provides next generation sequencing services with high throughput of reads at very fast turn around time with Ion Proton sequencing machine with typical sequence read outputs around 60 million to 85 million. The company also licenses its proprietary eKaryotype bioinformatics analysis package and provides the analysis through customized server or InKaryo pre-configured Amazon cloud EC2 instance.
Xitong Li, Ph.D., —former Director of Bioinformatics at Verinata Illumina— joins the Esperite team to drive the company’s scientific development. With a distinguished career in bioinformatics in the US spanning over 15 years, Xitong Li brings his experience in architecting solutions and delivering biomarker and genomic-based clinical diagnostic products to Genoma and ESPERITE. Before founding InKaryo, he was the Director of Bioinformatics at Verinata Illumina, Associate Director of Bioinformatics for Genomic Health, and contributed to Ingenuity Systems and Novartis Pharmaceuticals Corp. He received his Ph.D. in Cellular, Molecular and Developmental biology from the University of Rochester.
Xitong Li, founder of InKaryo:
We are committed to make high accuracy diagnostics affordable to people around the world by leveraging the next generation sequencing platform. We are excited to join ESPERITE to make our bioinformatics solutions widely available through GENOMA’s genomic tests and develop its new products, setting new standards of healthcare.
Through the examination of chromosomes in a sample, the karyotype test can identify causes of genetic disorders. InKaryo’s revolutionary eKaryotyping generates a digital ideograph of high resolution and high accuracy using NGS in combination with the most advanced bioinformatics processes. ESPERITE will utilize eKaryotype to detect cytogenetic aberrations with higher accuracy and higher resolution across the whole genome at a cost lower than all major CGH or CMA microarrays commercially available.
InKaryo’s NGS experimental protocol and proprietary bioinformatics analysis cover the full genome evenly with highly specific and accurate digital sequence output, reinventing karyotyping with a leap in quality yet at a fraction of the cost comparing array based comparative genomic hybridization (aCGH), or chromosomal microarray analysis (CMA). Sequencing will be to higher coverage and the test will look for large deletions and duplications uses advanced bioinformatics to find the large deletions and duplications.